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How many migraine patients need prolonged
(>1 year) preventive treatment?
Experience with topiramate




Abstract The usual recommended
duration of preventive treatment for
migraine is 3–6 months. Our aim
was to explore how many patients
attending a specialised clinic need
prolonged preventive treatment for
longer than one year. Eighty consec-
utive migraine patients who
received preventive treatment with
topiramate for 3 months with good
response and tolerability were
included in this observational study.
All patients continued on topiramate
until they had completed 6 months,
when this drug was stopped.
Topiramate was reintroduced if
there was a worsening. Topiramate
was kept for 6 more months and
then discontinued again. Those
patients whose headaches became
worse after this second withdrawal
received topiramate again and were
followed-up for at least half a year.
Headaches did not worsen after the
first withdrawal at 6 months in 40
patients (50%), while they clearly
worsened in the remaining 40
patients. At the end of the first year
only two patients out of these 40
(5%) discontinued topiramate and
did not notice an increase in
headache frequency after two
months. In conclusion, around half
of the patients attending a spe-
cialised clinic due to frequent
headache need preventive treatment
for more than one year. Our data
suggest that the current practice rec-
ommending periods of preventive
treatment of 3–6 months should be
reconsidered for many patients.
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Preventive treatment of migraine should be mandatory for
patients with frequent headaches. In spite of the fact that
at least 25% of those patients consulting meet criteria for
preventive treatment, this option is frequently forgotten,
as fewer than 10% of these patients receive preventatives
[1]. In addition, as most trials with preventatives last 3
months and because there are no clear recommendations
on the duration of this treatment [2], it not unusual that
preventive treatment is withdrawn after only three
months. In clinical practice many patients, however, clear-
ly worsen when this treatment is stopped after 3–6 months
[2–4]. The newest recommendations, in fact, begin to sug-
gest 6 instead of 3 months for the preventive treatment of
migraine.
Our aim was to explore how many migraine patients
attending a specialised clinic and treated with topiramate
need prolonged treatment for more than one year.
91
Patients and methods
We revised our long-term clinical experience with patients from
our headache clinic with a history of International Headache
Society [5, 6] classified migraine with more than 3 attacks per
month who received preventive treatment with topiramate for 3
months with good response (at least 50% reduction in frequen-
cy) and tolerability. Subjects had a history of migraine of at least
1 year. All patients continued on topiramate until they had com-
pleted a 6-month treatment period. Topiramate was then slowly
(25 mg per week) withdrawn. This drug was reintroduced if
there was an worsening after its withdrawal. Topiramate was
kept for 6 more months and then withdrawn again. Patients were
followed-up for at least 6 additional months. All patients com-
pleted at least this follow-up period. Patients were evaluated in
our clinic every three months.
Those patients whose headaches became worse after with-
drawal at the end of the first year received topiramate again. In
these patients we attempted to give up topiramate once a year. A
headache diary was provided to each subject.
Results
A total of 109 patients with more than 3 migraine attacks
per month were treated with topiramate in our clinic.
Twenty-nine (26.6%) either did not tolerate the drug (17
patients, 15,6%) or did not obtain a response (12 patients,
11%). Eighty (73.4%) migraine patients (64 women, age
range 25–75 years) with response and good tolerability to
topiramate after 3 months remained on topiramate. Forty-
eight (60%) met criteria for chronic migraine (17 with
overuse criteria), 23 (29%) for migraine without aura and
9 (11%) for migraine with aura. Headaches did not wors-
en after withdrawal in 40 (50%) patients who were fol-
lowed for at least 6 months (Fig. 1).
The remaining 40 patients (33 females, 26–75 years)
clearly saw their headaches worsened both in frequency
and intensity immediately after topiramate withdrawal and
received long-term follow-up. Twenty-six (65% of those
40 patients remaining in the study) met criteria for chron-
ic migraine (11 with overuse), 13 (32.5%) for migraine
without aura and 3 (7.5%) for migraine with aura.
Maintenance doses of topiramate at the end of the first year
of treatment ranged from 50 to 200 mg/day (mean 91
mg/day). In these patients, the number of days with
migraine headache per month as compared to the month
prior to treatment decreased from 19.9 to 7.7 (<65%), with
a total of 16 patients (40%) having an excellent (>75%
reduction in headache days) response. Fourteen (35%)
experienced during the first year of treatment a total of 16
adverse events: 7 showed cognitive symptoms, 5 distal
paraesthesias, 3 digestive symptoms and 1 asthenia. Body
weight did not change in 18 patients, increased (5 kg) in
one case and decreased in the remaining 21 (range 2–17
kg, mean 6.2 kg).
At the end of the first year only two patients (5%)
discontinued topiramate and did not notice an increase in
Fig. 1 Summary of results (*% of those 80
patients who were treated with topiramate for at
least 6 months)
109 subjects treated with topiramate (TP)
29 (26.6%) stop TP in the first 3 months 80 (73.4%) continue (good response/tolerability)
Poor tolerability Poor efficacy Withdrawal after 6 months
17 (15.6%) 12 (11%)
No worsening Worsening
40 (50%*) 40 (50%*)
Withdrawal after 1 year
No worsening Worsening
2 (5%*) 38 (95%*)
TP for one more year
F
92
headache frequency after two months. Therefore, 38
(95%) patients continued on topiramate for more than
one year due to an increase in headache frequency after
withdrawal.
At the time of writing this manuscript, 10 cases have
taken topiramate for between 1 and 2 years, 9 two years,
12 three years, 2 four years and 4 for five years. Five
patients have stopped topiramate after more than 2 years.
The reasons were: loss of efficacy (n=1), pregnancy (n=2)
and renal calculi (n=2 cases, both after 5 years).
Discussion
The main conclusion of this study is that around half of
the patients attending a specialised unit due to frequent
migraine headache need preventive treatment for more
than one year. From these data it seems clear that current
practice recommending periods of preventive treatment of
3–6 months should be reconsidered. This study has sever-
al important limitations, which make our conclusions pre-
liminary. First, these results are not applicable to all
migraine patients but only to those with frequent or very
frequent headache and in a specialised setting. Second,
this is an open, exploratory study, even though the con-
clusions indicate that controlled studies testing prolonged
preventive treatment of migraine are not only justified but
absolutely necessary. In fact, 40 out of 80 patients wors-
ened immediately after topiramate withdrawal at 6
months. All of them improved after topiramate was rein-
troduced. Only 2 (5%) of these 40 patients were able to
stop preventive treatment after one year, which suggests
that most patients whose headache worsens after the usual
withdrawal at 6 months actually need preventive treat-
ment for periods longer than one year. That actually hap-
pened in many of the patients we could follow for up to 5
years. Maybe for some patients a more careful titration
could be done as opposed to a longer period in the same
dose; for example, after 6 or 12 months of response, put
the patients on half the dose for another 6 months.
Patients with a higher need of prolonged treatment
were those with chronic migraine, especially if they
overused symptomatic treatments. These chronic migraine
patients have been shown to respond satisfactorily to top-
iramate [7, 8], even in the presence of overuse and in con-
trolled conditions [9, 10]. Interestingly, among the group
of responders in long-term treatment there was only one
patient whose headaches became worse while on topira-
mate. Adverse events were similar to those seen in previ-
ous clinical trials with topiramate [11–13]. None of these
patients discontinued the drug due to unbearable adverse
events in the first two years of treatment. Pregnancy and
renal colic were the reasons for stopping topiramate after
more than two years in a total of four patients. On the
other hand, our experience surely reflects the results
obtained with topiramate in daily practice in headache
clinics when treating migraineurs with frequent
headaches: around 15% of patients do not tolerate the
drug (mainly due to cognitive side effects), 10%–15% do
not respond, while the remaining 70% exhibit good (and
long-term) efficacy [7, 8].
The ideal duration of preventive treatment for
migraine is not known. These results show that half of
patients consulting with frequent migraine need prolonged
preventive treatment for more than one year and should be
taken into account in the clinical practice. This calls for
controlled studies testing the pros and cons and investi-
gating the profile of the patients who could obtain benefits
from this approach.
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